EyePoint Pharmaceuticals (NASDAQ: EYPT) reported Q3 EPS of ($0.49), $0.14 better than the analyst estimate of ($0.63). Revenue for the quarter came in at $10.01 million versus the consensus estimate of $11.61 million.

For earnings history and earnings-related data on EyePoint Pharmaceuticals (EYPT) click here.